

Stabilis



Cetuximab



錐喲搨錫

Erbitux

涓归害, 浼娉濂, 鍨板板矜, 鐳�犲登澶 鎶�墁墁錫 錫(二). 鏸
錫板害, 鋤勤撻澶�氬毖, 鍋ヤヤ姢旈簪, 鎵囧 冲舌, 澧X夕鍋
濂ユ逆錫 濮�旓旓鍨愨愨, 宸磋夕, 甯�岋, 寔峰涓, 鎸�忓錫
錫e, 錫拌夕钋 鍨�二滄, 鎸�哄, 姢旓旓鍨� 娉旓旓涓, 娉旓旓
(一)馭, 娉旓旓忓錫 簪, 鍨�二毖錫 鍨�怡吁, 鍨�怡+, 绉旓旓, 绉旓旓
凹錫 緇緇 灑间簪, 緇依涓, 鐳 馭, 鐳二涓, 鐳峰馭, 璪跨容
鐳 闂跨拏寤 榭 澈璪夸簪



婧舵恫緇冲晶鎶

		5 mg/ml	-20掳C		72			2220
		5 mg/ml	2-8掳C		1461			2220
		5 mg/ml	25掳C		72			2220
		5 mg/ml	2-8掳C		180			4819
		5 mg/ml	25掳C		3			4755
PVC		0.45 >> 5 mg/ml	25掳C		48			2220
PE		0.45 >> 5 mg/ml	25掳C		48			2220
PP		0.45 >> 5 mg/ml	25掳C		48			2220
PP		5 mg/ml	25掳C		3			4755
PP		5 mg/ml	4掳C		90			4755
POF		1 mg/ml	25掳C		3			4755
POF		1 mg/ml	4掳C		90			4755
POF		1,5 & 4 mg/ml	2-8掳C		30			4819
POF		1,5 & 4 mg/ml	25掳C		15			4819
EVA		0.45 >> 5 mg/ml	25掳C		48			2220



賽卜摺緋冲晶鎬 x 殍鏢攷礪

	> 25掳C			2220
--	--------	--	--	------



鐳煎 鎬

				
		Cetuximab Temocilline		2296
		Cetuximab		2220



鑿x崙閩旖緞



寮�曩鍑鐳�罔寮

	纒嶇被	鍑虹罔增鎬
2220	淪為獬淪	C茅tuximab (Erbix/罔) - Dossier scientifique Merck Serono 2015
2296	淪為獬淪	T茅mocilline (Negaban/罔) - R茅sum茅 des caract茅ristiques du produit Eumedica 2017
4755	鐳罔寮	Vieillard V, Le Guyader G, Jallades A, Astier A. Extended physicochemical stability of cetuximab in opened vials and infusion bags when stored at 4掳C and 25掳C. J Oncol Pharm Practice 2023
4819	鐳罔寮	Carpanese D, Rossi V, Di Paolo V, Quintieri L, Penna Zuccolotto G, Sebellin J, Saran C, Pipitone F, Miolo G, de Diana E et al. Prolonging the stability of cetuximab (Erbix/罔) and panitumumab (Vectibix/罔): An orthogonal assessment of physicochemical, biological and microbiological properties of original opened glass vials and diluted saline preparations. Int J Pharm 2024 ; 649: 123643.



瀛橘吁

	鋤櫛櫛𠂇𠂇		娉𠂇𠂇娉
	鋤𠂇𠂇鋤		娉𠂇𠂇𠂇𠂇𠂇
	瀛𠂇𠂇		鋤𠂇𠂇
	𠂇𠂇𠂇		娉 𠂇
	𠂇𠂇𠂇		𠂇 𠂇𠂇𠂇𠂇𠂇𠂇𠂇
	鋤𠂇𠂇𠂇𠂇 = 𠂇		鋤𠂇𠂇𠂇𠂇𠂇𠂇
	𠂇𠂇𠂇𠂇𠂇𠂇		𠂇𠂇𠂇
	鋤		鋤
	𠂇𠂇𠂇		鋤𠂇𠂇
	𠂇𠂇𠂇𠂇𠂇𠂇𠂇𠂇𠂇𠂇𠂇𠂇		𠂇𠂇𠂇
	鋤𠂇𠂇𠂇𠂇 𠂇		鋤𠂇𠂇𠂇𠂇𠂇
	NaCl 0,9%		鋤𠂇𠂇𠂇
	鋤𠂇𠂇𠂇		鋤𠂇𠂇𠂇
	𠂇𠂇𠂇𠂇𠂇𠂇𠂇𠂇𠂇𠂇𠂇		𠂇𠂇𠂇𠂇𠂇𠂇𠂇 x 𠂇𠂇𠂇𠂇𠂇
	𠂇𠂇		鋤𠂇𠂇 B
	鋤𠂇 𠂇		鋤𠂇𠂇
	娉𠂇𠂇		鋤 f 𠂇𠂇𠂇𠂇𠂇𠂇𠂇𠂇𠂇𠂇𠂇
	𠂇𠂇𠂇𠂇		鋤𠂇
	鋤 x 𠂇𠂇𠂇𠂇𠂇		𠂇𠂇𠂇𠂇𠂇𠂇
	𠂇𠂇𠂇𠂇𠂇𠂇		瀛橘吁